Results
MAY
42 male participants were assessed for study eligibility between 25th May 2017 and 13th February 2019; 10 failed the screening process leaving 32 participants who were enroled and randomised. Sixteen were assigned to AZD4017 (400 mg twice daily) plus prednisolone (20 mg daily) and 16 to placebo twice daily plus prednisolone (20 mg once-daily) (Fig. 